Recent advances of antibody drug conjugates for clinical applications
Antibody drug conjugates (ADCs) normally compose of a humanized antibody and small molecular drug via a chemical linker. After decades of preclinical and clinical studies, a series of ADCs have been widely used for treating specific tumor types in the clinic such as brentuximab vedotin (Adcetris®) f...
Main Authors: | Pengxuan Zhao, Yuebao Zhang, Wenqing Li, Christopher Jeanty, Guangya Xiang, Yizhou Dong |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Acta Pharmaceutica Sinica B |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383520305554 |
Similar Items
-
Antibody–Drug Conjugates—A Tutorial Review
by: Stephanie Baah, et al.
Published: (2021-05-01) -
Antibody–Drug Conjugates for Cancer Therapy
by: Umbreen Hafeez, et al.
Published: (2020-10-01) -
Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
by: Hao Chen, et al.
Published: (2017-08-01) -
Linkers Having a Crucial Role in Antibody–Drug Conjugates
by: Jun Lu, et al.
Published: (2016-04-01) -
Antibody Conjugates-Recent Advances and Future Innovations
by: Donmienne Leung, et al.
Published: (2020-01-01)